Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.

JCI insight - 23 Aug 2021

Lopez Ester, Haycroft Ebene R, Adair Amy, Mordant Francesca L, O'Neill Matthew T, Pymm Phillip, Redmond Samuel J, Lee Wen Shi, Gherardin Nicholas A, Wheatley Adam K, Juno Jennifer A, Selva Kevin J, Davis Samantha K, Grimley Samantha L, Harty Leigh, Purcell Damian Fj, Subbarao Kanta, Godfrey Dale I, Kent Stephen J, Tham Wai-Hong, Chung Amy W

Abstract excerpt

The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing antibodies and one of the most rapidly evolving domains, which can result in the emergence of immune escape mutations, limiting the effectiveness of vaccines and antibody therapeutics. To facilitate surveillance, we developed a rapid, high-throughput, multiplex assay able to assess the inhibitory response of antibodies to 24...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Neutralizing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to High-Throughput Screening Assays

Share to Immune Evasion

Share to Mutation

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 34251356
DOI: 10.1172/jci.insight.150012
PMCID: PMC8409985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay.PMID 34251356Read ↗

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutantsSemantic proximity Read ↗

Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 VariantsSemantic proximity Read ↗

Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.Semantic proximity Read ↗

Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity Read ↗

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read ↗

Comprehensive Mapping of Binding Hot Spots of SARS-CoV-2 RBD-specific Neutralizing Antibodies for Tracking Immune Escape VariantsSemantic proximity Read ↗

A multiplexed high-throughput neutralization assay reveals a lack of activity against multiple variants after SARS-CoV-2 infectionSemantic proximity Read ↗

Comprehensive Deep Mutational Scanning Reveals the Immune-Escaping Hotspots of SARS-CoV-2 Receptor-Binding Domain Targeting Neutralizing AntibodiesSemantic proximity Read ↗

Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody librarySemantic proximity Read ↗

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody librarySemantic proximity Read ↗

Two-dimensional multiplexed assay for rapid and deep SARS-CoV-2 serology profiling and for machine learning prediction of neutralization capacitySemantic proximity Read ↗

DESIGN OF A CHIMERIC ACE-2/Fc-SILENT FUSION PROTEIN WITH ULTRAHIGH AFFINITY AND NEUTRALIZING CAPACITY FOR SARS-CoV-2 VARIANTSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.